(RTTNews) - Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna's ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would help enable “in vivo” gene therapies for sickle cell disease and ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics Inc., announced its new three-year research collaboration with Vertex on Tuesday. Orna acquired Cambridge-based ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.